CONTINUUS Pharmaceuticals, Inc.

Woburn, MA · Founded 2012 · Biotech · Private

Continuous manufacturing system for pharmaceutical production using novel process technologies (heterogeneous crystallization and electrospinning)

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Woburn, MA
Founded: 2012
Latest Form D: $5M, Sep 2019
Total capital: $82.7M

Federal grants: $1.3M; 1 award · 2016; Rank in peer group#8 of 12
Private capital raised: $7.7M; 3 Form D · last Sep 2019; 86 months since last filing
Federal contracts: $73.7M; 2 awards · Health and Human S, Defense; Rank in Biotech#10 of 4373
Granted patents: 3; 8 pending · first 2020; Rank in peer group#2 of 12

Capital timeline

Latest events

Jan 2021Federal contractDefense · COVID-19 Dhhs Capacity Expansion To Provide Integrated Continuous Manufacturing Of Three Covid Related Pharmaceuticals. Contract Will Result In Capacity To Produce 100M Doses Per Year.$69.3M
Sep 2019Private capital raisedForm D · SEC · 3rd filing$5M
Sep 2016Federal contractHealth and Human S · Igf::cl::igf Baa Contract Titled, "advancement Of Integrated Continuous Manufacturing (icm)unit Operations."$4.4M
Feb 2016Federal grantNSF · Phase II · SBIR Phase II: Novel pharmaceutical manufacturing technologies to deliver more affordable medications to patients faster and with better quality$1.3M
Jun 2014Private capital raisedForm D · SEC · 2nd filing$2.5M
May 2013Private capital raisedForm D · SEC · 1st filing$265K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 12 peers

Line = median

Biotech · System

Federal grantsBelow median
Granted patents#2 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Salvatore MasciaResearcherExecutive Officer, DirectorLinked by $1.3M in grants as PI
Andrea SempriniDirectorNamed in SEC Form D filings
Bayan TakizawaDirectorNamed in SEC Form D filings
Bernhardt TroutDirectorNamed in SEC Form D filings
Jonathan FlemingDirectorNamed in SEC Form D filings
Mark BamforthDirectorNamed in SEC Form D filings

Show all 7 people

Nicola MaronDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 11

May 24, 2022GrantedContinuous Rotary Plate Filter and Methods of Use ThereofUSPTOUS 11,338,228
Dec 21, 2021GrantedContinuous Separator Bypass Systems and Methods of Use ThereofUSPTOUS 11,202,971
Jun 2, 2020GrantedContinuous Drum Dryer and Methods of Use ThereofUSPTOUS 10,667,547

Show all 11 patent records

Continuous Rotary Plate Filter and Methods of Use ThereofMay 24, 2022 · US 11,338,228Granted
Continuous Separator Bypass Systems and Methods of Use ThereofDec 21, 2021 · US 11,202,971Granted
Continuous Drum Dryer and Methods of Use ThereofJun 2, 2020 · US 10,667,547Granted
Continuous Rotary Plate Filter And Methods Of Use ThereofApplication PCTUS2017016589Pending
Continuous Drum Dryer And Methods Of Use ThereofApplication PCTUS2017016568Pending
Continuous Membrane Separator Bypass and Methods of Use ThereofApplication 62296219Pending
Continuous Drum Dryer and Methods of Use ThereofApplication 62291220Pending
Continuous Stirred Tank Reactors, Arrays Thereof, And Methods Of UseApplication PCTUS2025039482Pending
Continuous Rotary Plate Filter and Methods of Use ThereofApplication 62291219Pending
Continuous Stirred Tank Reactors, Arrays Thereof, And Methods Of UseApplication 63676586Pending
Continuous Separator Bypass Systems And Methods Of Use ThereofApplication PCTUS2017018379Pending

Sarepta TherapeuticsSimilar federal contract value in Biotech · $169M in contracts
CELLPHIRE, INCSimilar federal contract value in Biotech · $162M in contracts
VEDANTA BIOSCIENCES, INC.Similar federal contract value in Biotech · $99.1M in contracts
GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts
Spero Therapeutics, Inc.Similar federal contract value in Biotech · $65.6M in contracts
CRESTONE, INC.Similar federal contract value in Biotech · $61.5M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.